Villepinte, November 3rd, 2022: Guerbet today announced an agreement with Merative, formalizing the termination of their collaboration signed in July 2018. Guerbet today announced an agreement with Merative formalizing the termination of their collaboration initiated in July 2018. This partnership aimed to design, develop and market software solutions to help diagnose and monitor liver and prostate cancers. The termination follows Merative's strategic shift in how it delivers artificial intelligence within its imaging product portfolio.The new Asset Assignment and License Agreement grants Guerbet the ability and autonomy to pursue research and development, and plan for the market launch of Artificial Intelligence solutions. Assets developed during the partnership, including source code for application software, Artificial Intelligence algorithms and the associated intellectual property, are being transferred to Guerbet.

Guerbet is a pioneer in the contrast-agent field, with more than 90 years' experience, and is a leader in medical imaging worldwide. The company offers a comprehensive range of pharmaceutical products, medical devices, and services for diagnostic and interventional imaging, to improve the diagnosis and treatment of patients. With 8% of revenue dedicated to R&D and more than 200 employees distributed among its centers in France, Israel, and the United States, Guerbet is a substantial investor in research and innovation. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €790 million in revenue in 2018. For more information about Guerbet, please visit http://www.guerbet.com.

SCOTCH PLAINS, N.J., Nov. 29, 2019 /PRNewswire-PRWeb/ -- Anderson Publishing, Ltd., publishers of Applied Radiology, announce the launch of a new Artificial Intelligence (AI) Digital Community. This AI Digital Community is made possible by support from Guerbet, LLC, a leading manufacturer of contrast media, injectors, and digital solutions. Guerbet recently entered the AI market through a partnership with IBM Watson Health. "Guerbet is excited to support Applied Radiology in this endeavor, as the AI Digital Community aims to reach a wide audience of imaging professionals with important information about AI and its development and implementation in clinical practice," says Eric Smith, Marketing Manager, Medical Devices and Software for Guerbet. Kieran Anderson, Anderson Publishing Vice President and Group Publisher, added, "The AI Digital Community is designed to elevate the conversation around the growing use of AI in medical imaging for our digital audience."

I'm publishing this series to discuss a topic that I follow closely - cloud stocks, trends, strategy, acquisitions, and more. Please subscribe to my Cloud Stock Analysis series and never miss an article. Earlier this week, IBM (Nasdaq: IBM) declared its third quarter results that exceeded earnings expectations despite missing revenue estimates. The stock fell nearly 5% post the result announcement in the after-hours session. Revenues for the third quarter fell 3.9% over the year to $18.03 billion, missing the Street's forecast of $18.23 billion for the quarter.

From diagnostics and imaging to estimating the market impact of AI in the future, new AI and other innovative technologies caught the attention of many in the healthcare industry this year. Here are AI in Healthcare's top 10 AI and clinical innovation stories from 2018. A report released by Signify Research estimated the global market for AI in medical imaging is expected to see significant growth in the years ahead, topping $2 billion by 2023. Researchers from Brigham and Women's Hospital (BWH) in Boston developed "surgery in a pill" to treat type 2 diabetes by lowering blood glucose levels after a meal, with the approach detailed in a study. Cleveland Clinic physicians and scientists named the utilization of AI in healthcare as the second most important medical innovation for 2019.